The purpose of this review is to describe recent advances and changes in the evaluation and management of primary hyperparathyroidism (PHPT).
INTRODUCTION
Primary hyperparathyroidism (PHPT) is characterized by hypercalcemia and serum parathyroid hormone (PTH) levels that are either frankly elevated or inappropriately normal. The condition is caused by excessive secretion of PTH from one or more of the four parathyroid glands [1] . PHPT was first described in the early 20th century in both Europe and the United States [2] . At that time, PHPT typically presented in its 'classic form' with severe hypercalcemia and a complex of constitutional, renal, skeletal, gastrointestinal and neuropsychological symptoms [1, 3] . Early descriptions frequently included polyuria and nephrolithiasis; osteitis fibrosa cystica (characterized clinically by bone pain and fractures); anorexia, weight loss, constipation and pancreatitis; weakness and 'mental disturbances' as well as lassitude [2, 3] .
Due to the routine screening of serum calcium, as part of multichannel autoanalysis that began in the 1970s in the United States and many other parts of the world, PHPT evolved in those geographic locales from a rare and symptomatic disease to one that, today, is common and most often presents asymptomatically with mild hypercalcemia discovered incidentally [1] . In the recent past, even further evolution of the biochemical profile of PHPT has occurred in some parts of the world. In the United States, higher vitamin D intake has led to higher serum 25-hydroxyvitamin D (25OHD) and lower PTH levels as compared with 20 years ago [4] . Other biochemical forms of PHPT have also been recently recognized, such as a 'normocalcemic variant' in which serum calcium levels are normal but PTH levels are persistently elevated [5] .
New data have led to recent changes in the recommended evaluation and management of PHPT [5] . Due to advances in genetics, it is now recognized that 5-10% of patients may have a germline mutation associated with inherited PHPT. Due to their greater availability and reduced cost, genetic testing is clinically feasible in patients suspected of having a genetic cause (i.e. those who are young and/or present with a personal or family history of multiple endocrine gland overactivity). Although asymptomatic PHPT has long been associated with subclinical manifestations such as low bone density or hypercalciuria, recent investigations are noting, in addition, clinically silent vertebral fractures and nephrolithiasis when imaging is directed to uncover these complications [6] . For this reason, more extensive renal and skeletal assessment is now recommended [5] . Newer techniques for noninvasively evaluating the trabecular skeleton, such as vertebral fracture assessment (VFA) and trabecular bone score (TBS), in addition to dual-energy X-ray absorptiometry (DXA), are helpful when available [5] . Criteria for parathyroidectomy (PTX) in patients with asymptomatic PHPT are broader and now include evidence for kidney stones, nephrocalcinosis, vertebral fractures, hypercalciuria or other urinary stone risk factors, in addition to established surgical criteria based on age, serum calcium, DXA and renal function [5] .
Data from randomized clinical trials (RCTs) have become available regarding the effect of PTX upon both classical (skeleton) and nonclassical (psychological function and cardiovascular health) targets. Recent RCTs have confirmed results from observational studies with regard to beneficial effects of PTX upon the skeleton but have not consistently shown improvements in nonclassical symptoms. This is one reason why nonclassical features of PHPT are not generally listed as an indication for PTX [7] . Advances in parathyroid localization and surgery allow for minimally invasive PTX in many centers. Although PTX remains the only cure for PHPT, medical therapies can usefully address some complications such as reduced bone mass and hypercalcemia. In this review, we summarize the pathogenesis, diagnosis, presentation, evaluation and treatment of PHPT with an emphasis on recent advances in the field.
EPIDEMIOLOGY
The estimated incidence of PHPT covers a broad range of 0.4-82 cases per 100 000 [8] [9] [10] . When measurement of the serum calcium concentration became routine, in the early 1970s, this disease, which used to be considered rare, became much more common. Along with the increase in incidence, many of these individuals were discovered incidentally and found not to have any classic features of the disease, except for hypercalcemia [11] . Hence, the term, 'asymptomatic' PHPT was applied to this increasingly large patient population. We have witnessed, in the last several decades, yet another increase in incidence due, in all likelihood, to targeted screening in postmenopausal women with osteoporosis [9, 12, 13] . The most common time when PHPT is discovered is the first decade after menopause. Indeed, about half of all patients with PHPT are postmenopausal women and the disease favors women by a 3 : 1 margin. Incidence increases with age, although PHPT can occur at any age [8, 14] . Incidence is also higher among African-Americans than other racial groups [8] .
CAUSE
PHPT results from excessive secretion of PTH from one or more of the parathyroid glands. The disorder is caused by a solitary parathyroid adenoma in 80% of cases, while hyperplasia of all four glands occurs in 15 -20% [1, 15] . In a small percentage of patients, PHPT is due to multiple adenomas. Parathyroid carcinoma accounts for less than 1% of all cases of PHPT [15] . Inherited forms of PHPT are present in 5-10% of cases [16] [17] [18] . The germ-line mutations associated with hereditary forms of PHPT are shown in Table 1 [16] [17] [18] . A recent National Institutes of Health study found germ-line mutations in 60% of patients with a positive family history of PHPT [19 && ]; age 45 years old or less, male sex, multigland disease and parathyroid carcinoma were risk factors for having a germ-line mutation
KEY POINTS
Over the past half century, the clinical presentation of PHPT has evolved from a highly symptomatic disease to one that is typically asymptomatic, but often with subclinical skeletal and renal manifestations.
Several different clinical presentations of PHPT are possible. Screening practices and the prevalence of vitamin D deficiency all influence which clinical phenotype of the disease will predominate.
The most recent guidelines call for a proactive assessment of renal and skeletal involvement in asymptomatic PHPT as well as broader indications for PTX due to frequent subclinical involvement of these target organs.
Various pharmacological treatments improve bone mineral density or reduce serum calcium in those who cannot undergo surgery, though no single medical therapy can accomplish both and surgery remains the only cure.
[19 && ]. Because this study was conducted in a referral center for hereditary PHPT, it is unclear how generalizable these findings are to other clinical settings.
PHPT is usually, however, sporadic (without family history, other endocrine organ tumors, hyper-secretion or hypo-secretion or syndromic features). Although external neck radiation and lithium therapy are risk factors for the development of sporadic PHPT, most patients do not report these exposures [20, 21] . Chronically, low-calcium intake and higher body weight are also reported to be risk factors [22, 23] . Celiac disease is a risk factor for PHPT, suggesting that chronic malabsorption, associated with a secondary, compensatory hyperparathyroidism, could lead to PHPT [24] . Hypertension and furosemide are associated with greater risk of developing PHPT, though it is possible surveillance bias accounts for this [25] . Thiazide diuretics are now thought to unmask the hypercalcemia of PHPT rather than cause it [26 & ].
DIAGNOSIS
In all forms of PHPT, there is loss of normal feedback of serum calcium levels to suppress the synthesis and secretion of PTH, resulting in a shift of the calcium-PTH relationship rightward ( Fig. 1) ]. The PTH level should be repeated several weeks after stopping biotin. Thiazide diuretics, which can elevate serum calcium, should be discontinued for 3 months before confirming the diagnosis. Most remain hypercalcemic off thiazides and the diagnosis of PHPT can then be made [1] . The decision to stop lithium should be made only with the concurrence and supervision of the patients' mental health providers. As is the case with discontinuing thiazide diuretics, when hypercalcemia surfaces in the context of chronic lithium therapy, patients will in all likelihood be shown to have PHPT. PHPT must be distinguished from familial hypocalciuric hypercalcemia (FHH); FHH is due to an autosomal dominant mutation in the calcium-sensing receptor (CASR) gene, which increases the set point for serum calcium [18] . The serum biochemical profile is similar in FHH and PHPT. FHH is considered to be a distinct entity from PHPT by ]. Nonparathyroid causes of hypercalcemia are distinguished from PHPT by suppressed PTH levels (<20 pg/ml).
Another biochemical form of PHPT is designated normocalcemic PHPT (NPHPT), because the albumin-adjusted total calcium and ionized calcium are always normal while the PTH is always elevated.
Of course, such a biochemical presentation could be due to secondary hyperparathyroidism [28] . In contrast to the hypercalcemic form of PHPT, in which the serum calcium is sometimes normal, the serum calcium level in NPHPT is always normal. To verify NPHPT, the secondary hyperparathyroid states have to be excluded: vitamin D deficiency, renal insufficiency (estimated glomerular filtration rate <60 ml/ min), idiopathic hypercalciuria, malabsorption and certain medications (thiazides, bisphosphonates and denosumab) [32] . With regard to vitamin D deficiency, most experts feel that the 25OHD level should be consistently more than 30 ng/ml, regardless of whether one considers 20 or 30 ng/ml the normal threshold. Demonstrating a high PTH even with a 25OHD consistently more than 30 ng/ml helps to make vitamin D deficiency and/or resistance a less likely explanation for the increase in PTH.
Another theoretical form of PHPT has been recently reported in which a parathyroid adenoma is verified pathologically in the context of normal serum calcium and PTH levels [33, 34] . This 'normocalcemic-normohormonal' phenotype, however, is not yet recognized as another variant of PHPT. With the widespread use of thyroid ultrasound, incidentally discovered parathyroid adenomas, in the absence of biochemical confirmation of disease, will likely become a more common issue.
CLINICAL PRESENTATION
Several different presentations of PHPT are possible and were originally described successively in time [3, 14, 32] . The classical symptomatic presentation was described first; later, asymptomatic PHPT emerged due to biochemical screening, and most recently, the normocalcemic variant was discovered due to the frequent measurement of PTH during evaluations for bone loss or osteoporosis. However, these three forms of PHPT contemporaneously exist today. Which presentation predominates depends upon population-specific and geographic-specific screening practices. In regions (Middle East, Asia, South Africa and Latin American) and populations (young women and men) where biochemical screening is not routine, symptomatic PHPT is the most common form and PHPT will appear to be uncommon because it is only discovered when symptomatic [35-38,39,40 41, 42] . In areas (United States, Western Europe and Turkey) and populations (postmenopausal women) where screening is routine, asymptomatic PHPT will predominate and the incidence of PHPT is higher [14, 43] . Changes in screening practices within populations can lead to a shift in the relative frequency of symptomatic vs. asymptomatic disease. In China, for example, there has been a shift toward more asymptomatic disease with introduction of the multichannel autoanalyzer [35, 44, 45] . Finally, in centers where PTH is frequently measured even among those with a normal serum calcium concentration, NPHPT will emerge as a clinical entity [32] .
Classical primary hyperparathyroidism
Classical PHPT is the predominant mode of presentation when calcium is not routinely measured [2, 3] . In addition, severe and prolonged vitamin D deficiency may contribute to development of classical PHPT [46, 47] . Classical disease is characterized by marked hypercalcemia (typically >12 mg/dl) and its multisystemic constitutional, skeletal, renal, gastrointestinal, neuropsychological and cardiovascular manifestations [2, 3] . In such patients, mortality is increased [2, 3] . Early descriptions in the United States frequently were associated with polyuria, polydipsia, renal failure, nephrolithiasis and nephrocalcinosis; osteitis fibrosa cystica, characterized clinically by bone pain and fractures, and radiographically by compression fractures, salt and pepper demineralization of the skull, subperiosteal bone resorption, bone cysts and brown tumors; anorexia, weight loss, constipation, peptic ulcer disease and pancreatitis; weakness, fatigue, 'mental disturbances', and lassitude; short-QT interval and cardiovascular death [2, 3, 48, 49] .
Asymptomatic and 'mild' primary hyperparathyroidism
The biochemical profile of asymptomatic PHPT typically reveals modest hypercalcemia (within 1 mg/dl above the upper assay limit) and a PTH level within two times above the upper limit [14] . The term 'asymptomatic' is useful because of its historical roots but it is somewhat of a misnomer because patients often have constitutional, psychological and cognitive complaints and/or evidence of subclinical end-organ (skeletal and renal) damage [50] . Whether some of these manifestations of asymptomatic PHPT reflect direct effects of PTH or hypercalcemia on nontraditional targets including the cardiovascular system and neuropsychological function is controversial.
Skeletal disease DXA tends to show preferential loss of bone mineral density (BMD) at cortical sites such as the distal onethird site of the forearm, whereas sites rich in cancellous bone such as the lumbar spine are relatively spared [51] . This pattern was thought to reflect the catabolic vs. anabolic effects of PTH on different skeletal compartments as seen on iliac crest bone biopsies [52] . Newer noninvasive skeletal imaging technologies, however, offer new insight. TBS, which provides an indirect assessment of trabecular microstructure from the DXA image and predicts fracture independently of BMD, demonstrates in PHPT trabecular deterioration despite preserved BMD by DXA [53, 54] . High-resolution peripheral quantitative computed tomography (HRpQCT), a technology that noninvasively and directly measures skeletal microstructure, shows trabecular deficits at the radius and tibia (Fig. 2) [55] [56] [57] . The apparent high trabecular density in some studies may result from detrimental trabecularization of the endocortical bone surface [57] . These recent findings, pointing to abnormalities in the trabecular compartment of bone, help to account for the increased risk of vertebral fractures observed in PHPT prior to the advent of these technologies [58] [59] [60] [61] . In cross-sectional studies, TBS has also been associated with prevalent vertebral fracture in PHPT [62] . The 2014 Guidelines for the Management of Asymptomatic PHPT took these new findings into account by recommending screening for vertebral fractures (by radiographs or VFA) and PTX if present [5, 6] . Further evidence in support of this recommendation comes from a recent RCT associating successful PTX with a reduction in vertebral fracture risk that was of borderline statistical significance [63] .
The effect of vitamin D deficiency on skeletal manifestations of asymptomatic, mild PHPT has also been a subject of recent investigation [53, [64] [65] [66] . Low 25OHD levels can cause high PTH levels, based upon the known reciprocal physiological relationship between vitamin D and PTH. Lower 25OHD levels are also associated with higher PTH levels in PHPT. In those with 25OHD levels less than 30 ng/ml, BMD is lower at the one-third radius, reflecting the higher PTH [65, [67] [68] [69] . Significantly, vitamin D repletion may improve BMD, particularly at the spine [68] . Although vitamin D deficiency is still of concern in PHPT, its prevalence has recently declined due to widespread use of vitamin D selfsupplementation [4] .
Renal disease
The most common renal effects of PHPT are hypercalciuria and nephrolithiasis [70] . Kidney stones are present in 10-20% of patients when defined by clinical 'attacks' [14, 70, 71] . Screening for subclinical nephrolithiasis, as recommended by the most recent guidelines, indicates that the prevalence is much higher [5, 6, 70, 72, 73 & ]. In the United States, one recent study indicates that occult urolithiasis assessed by renal ultrasound (Fig. 3) is present in about one-fifth of asymptomatic patients [73 & ]. An even higher percentage of occult nephrolithiasis (36%) was recently reported by Cipriani et al. [6] from an Italian cohort with asymptomatic PHPT. On the other hand, overt symptoms related to renal manifestations of PHPT (e.g. nephrocalcinosis, polyuria and polydipsia) are uncommon today in the United States [70, 73 & ]. Currently, renal dysfunction occurs only in approximately 15% and in most is not clearly due to PHPT or its severity [74] [75] [76] . Rather, traditional risk factors (age, hypertension, antihypertensives and glucose) were associated with renal dysfunction in a recent study of PHPT [75] . Reassuringly, prospective data indicate that renal function remains stable in asymptomatic PHPT over long follow-up periods and, moreover, PTX does not improve renal function [7, 14, [77] [78] [79] .
Cardiovascular disease
Although mortality due to cardiovascular disease has been linked to classic symptomatic and severe PHPT [48] , limited data suggest no increased mortality in those with 'mild' or asymptomatic disease [80, 81] . Recent studies have investigated multiple mechanisms of cardiovascular disease, including hypertension, left ventricular hypertrophy (LVH) and coronary artery disease (CAD) among others. Hypertension is associated with PHPT but is not reversible with PTX [48] . LVH has been documented in PHPT in many studies [48] . A meta-analysis indicated that PTX results in a decline in ventricular mass and that higher preoperative levels of PTH predict a greater cardiovascular benefit [82] . However, it was impossible to disentangle disease severity from study design as observational and short studies tended to include those with more biochemically, severe PHPT compared with RCTs and longer studies. When CAD is present in PHPT, it is due to traditional risk factors rather than PHPT itself, though coronary flow reserve may be affected [83] [84] [85] . Valve calcification, seen in severe PHPT, may be more extensive and related to PTH level when present in those with mild PHPT but it is not reversible with PTX [86] [87] [88] . There are inconsistent data regarding intima-media thickness and endothelial function [89] [90] [91] [92] [93] . Most studies have reported increased vascular stiffness, sometimes associated with PTH levels, in mild PHPT, but its reversibility with PTX is variable [93] [94] [95] [96] . Given conflicting data regarding the cardiovascular complications of PHPT and reversibility with PTX, most experts do not recommend cardiovascular evaluation solely because of PHPT or consider cardiovascular disease to be an indication for PTX [5] .
Neurological and psychiatric disease
Descriptions of classical PHPT include neurological and psychiatric features, but the extent to which these are part of the modern phenotype of PHPT is controversial [2, 3] . In addition, if there is a relationship, the underlying mechanisms are unclear. The proximal muscle weakness and atrophy seen in classical PHPT are not seen today. Many studies suggest, however, that even 'mild PHPT' is associated with depression, anxiety, lassitude, decreased quality of life (QOL), sleep disturbances and cognitive changes [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] . Many observational studies have noted improvement after PTX [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] . Three RCTs have investigated the reversibility of reduced QOL and psychiatric symptoms but came to different conclusions [7, 79, 113] ; one RCT suggested that PTX prevents worsening of QOL and improves psychiatric symptoms [113] , another RCT indicated no benefit [7] and the third showed improvement in QOL [7, 79] . At present, most experts do not recognize cognitive or psychiatric symptoms as a sole indication for PTX due to lack of clear reversibility in RCTs, the inability to predict improvement and a lack of a well defined mechanism [5] .
Rheumatological and gastrointestinal features
Classical PHPT was rarely associated with hyperuricemia, gout and calcium pyrophosphate crystal deposition [114] [115] [116] . Pseudogout, or synovitis caused by calcium pyrophosphate crystal deposition, has been reported after PTX, though the mechanism is unclear [117] . Overt rheumatologic manifestations are mainly a historical phenomenon and not part of the spectrum of modern disease [118] . Pancreatitis and peptic ulcers are not a feature of PHPT today due to mild hypercalcemia, although there are conflicting data concerning constipation [119, 120] .
Normocalcemic primary hyperparathyroidism
Both the Third and Fourth International Guidelines for the Management of Asymptomatic PHPT recognized NPHPT as a phenotype of PHPT [28, 121, 122] . Although the clinical manifestations of NPHPT would be predicted to be milder vs. the hypercalcemic variant, many case series suggest high rates of osteoporosis, fractures and kidney stones, likely due to selection bias as NPHPT is often diagnosed after such a clinical event [32, 123, 124] . Limited data from a community cohort suggest that there is no difference in BMD between those with NPHPT and those with normal PTH [125] . Almost no data (ND) exist regarding nonclassical manifestations in NPHPT [126] . The natural history of NPHPT is variable. NPHPT can evolve into typical hypercalcemic PHPT, but cohort studies found that only 0.6-19% become hypercalcemic [32, 125, 127] .
EVALUATION
The recommended evaluation of a patient with PHPT is shown in Table 2 [5] . Three-site DXA should routinely be obtained due to low BMD or osteoporosis often isolated to the forearm [128 & ]. Because many patients with asymptomatic PHPT have compression fractures, vertebral imaging should be acquired with radiographs or VFA (a spine radiograph obtained on a densitometer). Other modalities for assessing trabecular deterioration can be considered (TBS, HRpQCT etc.) [5] . Due to the recent recognition that renal stones are seen commonly in asymptomatic PHPT, renal imaging [by abdominal radiograph, ultrasound or computed tomography (CT)] is recommended [5, 6, 72, 73 & ].
TREATMENT OF PRIMARY HYPERPARATHYROIDISM

Surgery and preoperative localization
The only cure for PHPT is surgical removal of the overactive parathyroid gland(s) [129] . Most studies suggest that successful PTX leads not only to normalization of all biochemical indices but improvement in BMD and a reduction in fractures and kidney stones [7, 14, 79, 130, 131, 132 && ]. Although a 2016 meta-analysis of PTX vs. surveillance indicated no benefit of surgery across bone health, QOL and neuropsychiatric symptoms, it was limited by lack of power having excluded many relevant studies [133] . In contrast, a 2018 meta-analysis of PTX vs. observation indicated that cohort studies demonstrated a reduced risk of fracture in PHPT patients, while RCTs showed an increase in BMD [134 && ]. New data using HRpQCT indicate improved volumetric BMD, bone microarchitecture and strength at the distal radius and tibia, while there are conflicting data regarding whether TBS changes after PTX [56, 135, 136 
& ]. Even in NPHPT, limited data suggest that PTX may increase BMD [124] .
In patients who are symptomatic of hypercalcemia or who have target organ sequelae (fractures or nephrolithiasis), PTX is indicated unless there are medical contraindications [5] . Whether patients with asymptomatic PHPT should undergo PTX has been addressed by four International Workshops for the Management of Asymptomatic PHPT. The most recent, revised guidelines for surgery from the 4th conference are summarized in Table 2 [5] . Recent data suggest that these guidelines do, indeed, influence physician/patient decisions to undergo PTX [138 & ]. Although evidence-based recommendations are lacking in NPHPT, surgery is suggested if patients become hypercalcemic and have other indications (as shown in Table 2 ) for PTX; PTX is also considered in NPHPT when there is disease progression regardless of hypercalcemia [5] .
Surgical guidelines from other societies are more liberal than those of the Fourth International Workshop for the Management of Asymptomatic PHPT [139 & ]. The American Association of Endocrine Surgeons also recommend PTX in those with cognitive/ psychiatric symptoms attributable to PHPT, suggest offering PTX to those with cardiovascular disease (other than hypertension) and consider muscle weakness, impaired functional capacity and abnormal sleep patterns in decisions. It is important to note that even in those not meeting PTX guidelines, surgery is not inappropriate as long as the diagnosis Although calcium and PTH will normalize in most post-PTX, some patients have persistently elevated PTH with normal calcium after PTX consistent with secondary hyperparathyroidism. Prevalence estimates range from 3 to 46% and this finding is associated with higher preoperative PTH, low preoperative 25OHD, poorer renal function and greater adenoma weight, but it does not seem to increase risk for PHPT recurrence [141] . On the other hand, hungry bone syndrome with low serum calcium post-PTX appears to be uncommon today and may be related to extent of preoperative PTH level [142] . Recent data from the Mayo Clinic suggest that patients with normohormonal PHPT (i.e. high calcium with nonsuppressed PTH) may be more likely to have negative sestamibi scans, more extensive surgery, and have lower cure rates compared with those with high calcium and high PTH [143 & ].
Nonsurgical management
Patients who do not undergo surgery must be monitored (Table 2 ) [5] . If any surgical guideline is met during follow-up, PTX should be considered. Longterm observational data indicate that biochemistries remain stable for many years in those followed nonoperatively [14] . However, 15-year data suggest that BMD starts to decline at cortical sites after 10 years of observation and almost 40% of patients developed one or more indications for PTX over 15 years of follow-up [130] . As noted, compared with observation, PTX is associated with a BMD benefit and fracture risk reduction [7,63,79,130,131,132 && ,144,145] . Some data also suggest that surgery is more costeffective than medical treatment or observation in those not meeting guidelines for PTX [146 & ].
If patients are monitored, the Fourth International Workshop recommends following the Institute of Medicine guidelines with regard to calcium intake [147] . Guidelines further endorse replacing vitamin D to levels of 21-30 ng/ml with conservative doses of vitamin D (600-1000 IU daily) on the basis of data showing that vitamin D treatment lowers PTH levels [147] . Higher levels of vitamin D may be beneficial. A 2014 RCT of cholecalciferol (2800 IU daily vs. placebo) indicated that treatment increased 25OHD levels, lowered PTH and increased spine BMD without increasing serum or urine calcium [68] .
If PTX is not possible or is refused, various medical therapies can be considered in those with osteoporosis, fracture or calcium levels in the range that would cause symptoms. Small RCTs indicate that alendronate and HRT increase BMD at multiple skeletal sites in PHPT compared with placebo, but most show no change in serum calcium [147] [148] [149] [150] [151] [152] . In fact, a meta-analysis indicated that antiresorptive and surgical interventions produce similar, beneficial effects on BMD in PHPT [153] . The first analysis to assess denosumab suggests that it is effective at increasing BMD in older women with osteoporosis and PHPT, though the data were observational and retrospective [154 & ]. Whether medical treatment reduces fracture in PHPT is unclear. A large retrospective cohort study suggested that bisphosphonate therapy did not reduce fracture risk in patients with PHPT and was no more effective than observation, though the nonrandomized design may have influenced this result [132 && ]. In those with hypercalciuria, limited data suggest that thiazides may decrease urinary calcium excretion without increasing serum calcium, but the impact on nephrolithiasis is unclear [155] [156] [157] .
Cinacalcet, a type-2 calcimimetic, binds to the CASR and increases its sensitivity. Cinacalcet reduces serum calcium in PHPT and maintains long-term normocalcemia across a wide spectrum of disease severity [147, 158, 159] . Neither BMD nor urinary calcium excretion improves with treatment. Further, there are no data regarding nephrolithiasis risk reduction [147] . Cinacalcet was approved for PHPT by the US Food and Drug Administration in 2011 for the 'treatment of severe hypercalcemia in patients with PHPT who are unable to undergo PTX' [147] . Financial support and sponsorship The current work was supported, in part, by NIH grants DK 32333 and DK 104105.
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